Drug susceptibility testing of Mycobacterium tuberculosis against second-line drugs using the Bactec MGIT 960 System
Rodrigues, C.; Jani, J.; Shenai, S.; Thakkar, P.; Siddiqi, S.; Mehta, A.
International Journal of Tuberculosis and Lung Disease the Official Journal of the International Union Against Tuberculosis and Lung Disease 12(12): 1449-1455
2008
ISSN/ISBN: 1027-3719 PMID: 19017456 Accession: 052721412
To establish the critical test concentrations for seven second-line anti-tuberculosis drugs in the Bactec Mycobacterial Growth Indicator Tube (MGIT) 960 TB system and to evaluate its efficacy compared to the Bactec 460 TB system. This study was carried out in three phases. In Phase I, pan-susceptible strains were tested to establish the minimum inhibitory concentration; in Phase II, mostly resistant strains were tested to determine a critical test concentration; and in Phase III, actual clinical isolates were tested to validate the optimal critical concentrations established in Phases I and II. The critical concentrations established for seven second-line drugs with the Bactec MGIT 960 system are amikacin 1.0 microg/ml, capreomycin 2.5 microg/ml, kanamycin 2.5 microg/ml, ofloxacin 2.0 microg/ml, moxifloxacin 1.0 microg/ml, ethionamide 5.0 microg/ml and para-amino salicylic acid 4.0 microg/ml. The Bactec MGIT 960 System is an accurate and reliable method for rapid drug susceptibility testing (DST) of Mycobacterium tuberculosis against second-line drugs. In the present study, few of the strains were resistant to fluoroquinolones and further DST for this group is required.